Last reviewed 2026-04-22 · How we verify

Teprotumumab N01

Teprotumumab is a human monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R) signaling to reduce inflammation and fibrosis in thyroid eye disease.

Teprotumumab is a human monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R) signaling to reduce inflammation and fibrosis in thyroid eye disease. Used for Thyroid eye disease (TED) / Graves' ophthalmopathy.

At a glance

Mechanism of action

Teprotumumab binds to and blocks the IGF-1 receptor on orbital fibroblasts and immune cells, preventing IGF-1-mediated activation and proliferation that drives the inflammatory and fibrotic processes characteristic of thyroid eye disease (TED). By inhibiting this pathway, it reduces orbital inflammation, decreases hyaluronic acid production, and limits extraocular muscle expansion, thereby improving eye symptoms and disease progression.

Approved indications

• Thyroid eye disease (TED) / Graves' ophthalmopathy

Common side effects

• Infusion reactions
• Hyperglycemia
• Upper respiratory tract infection
• Nausea

Key clinical trials

• Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. (NA)
• A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease (PHASE4)
• A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Teprotumumab N01 CI brief — competitive landscape report
• Teprotumumab N01 updates RSS · CI watch RSS
• Innovent Biologics (Suzhou) Co. Ltd. portfolio CI